KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Research & Development (2016 - 2025)

Fulgent Genetics' Research & Development history spans 11 years, with the latest figure at $14.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 16.98% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $53.9 million, up 10.42%, while the annual FY2025 figure was $53.9 million, 10.42% up from the prior year.
  • Research & Development for Q4 2025 was $14.2 million at Fulgent Genetics, up from $13.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $14.2 million in Q4 2025 and bottomed at $5.3 million in Q2 2021.
  • The 5-year median for Research & Development is $9.9 million (2023), against an average of $9.9 million.
  • The largest annual shift saw Research & Development surged 187.29% in 2021 before it fell 0.04% in 2025.
  • A 5-year view of Research & Development shows it stood at $7.5 million in 2021, then increased by 14.0% to $8.5 million in 2022, then skyrocketed by 40.46% to $12.0 million in 2023, then grew by 1.35% to $12.1 million in 2024, then grew by 16.98% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Research & Development are $14.2 million (Q4 2025), $13.9 million (Q3 2025), and $13.5 million (Q2 2025).